Associated Papers
Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.
Guerineau H et al.
American Journal of Hematology, 2025
39654506 (PubMed )
Supplement: supplement_1.pdf
Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis.
Demajo S et al.
Cancer Discovery, 2024
38722595 (PubMed )
Supplement: cd-23-1416_supplementary_table_s3_suppst3.xlsx › Supplemental_table_drivers
Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Flynn PA et al.
Frontiers in Immunology, 2024
38495876 (PubMed )
Supplement: Table_1.xlsx › summary
Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.
Garrote M et al.
Cancers, 2023
37568719 (PubMed )
Supplement: cancers-15-03904-s001.zip › cancers-2478235-supplementary.pdf
Increased clonal hematopoiesis involving DNA damage response genes in patients undergoing lung transplantation.
Tague LK et al.
Jci Insight, 2023
36853803 (PubMed )
Supplement: jciinsight-8-165609-s144.pdf
Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation.
Soerensen JF et al.
Bone Marrow Transplantation, 2022
Association of clonal hematopoiesis with chronic obstructive pulmonary disease.
Miller PG et al.
Blood, 2022
34855941 (PubMed )
Supplement: 10.1182-2021013531_bloodbld2021013531-suppl1.pdf
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial.
Ayala R et al.
Cancers, 2021
34070172 (PubMed )
Supplement: cancers-13-02458-s001.zip › cancers-1203671-supplementary › Table_S8.xlsx › Hoja2
Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation.
Rotunno G et al.
Blood, 2019
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
Gelsi-Boyer V et al.
Journal of Hematology & Oncology, 2012
Select a paper to view details